Published on 8 Aug 2023 on Zacks via Yahoo Finance
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.74 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -81.40%. A quarter ago, it was expected that this company would post a loss of $0.77 per share when it actually produced a loss of $0.21, delivering a surprise of 72.73%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.